Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $718197.0.

  • Inhibikase Therapeutics' Change in Accured Expenses rose 46618.26% to $718197.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 39314.35%. This contributed to the annual value of $420075.0 for FY2024, which is 40334.49% up from last year.
  • According to the latest figures from Q3 2025, Inhibikase Therapeutics' Change in Accured Expenses is $718197.0, which was up 46618.26% from -$575063.0 recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Change in Accured Expenses ranged from a high of $1.0 million in Q3 2021 and a low of -$1.3 million during Q3 2022
  • Moreover, its 5-year median value for Change in Accured Expenses was $245372.0 (2021), whereas its average is $159128.9.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 1560569.11% in 2022, then crashed by 27347.03% in 2024.
  • Inhibikase Therapeutics' Change in Accured Expenses (Quarter) stood at $810751.0 in 2021, then tumbled by 83.67% to $132394.0 in 2022, then skyrocketed by 203.44% to $401740.0 in 2023, then grew by 29.1% to $518656.0 in 2024, then skyrocketed by 38.47% to $718197.0 in 2025.
  • Its Change in Accured Expenses was $718197.0 in Q3 2025, compared to -$575063.0 in Q2 2025 and $833219.0 in Q1 2025.